Tous Actualités
Suivre
Abonner Merck Healthcare Germany GmbH

Merck Healthcare Germany GmbH

Merck KGaA Names Engle New Generics Group Regional Director, North America

Darmstadt, Germany (ots/PRNewswire)

Merck KGaA today announced
an organizational change in the Merck Generics Group (MGG), naming J.
Melville ("Mel") Engle to the post of MGG Regional Director, North
America. Mr. Engle will retain his current position of President and
Chief Executive Officer of Napa, CA-based DEY, L.P., a Merck
subsidiary.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060105/NETH013 )
Merck's Generics Group currently ranks among the top three global
suppliers in the highly competitive generics market.
In addition to his day-to-day responsibilities at DEY, Mr. Engle
will oversee Genpharm Inc., one of Canada's largest generic drug
companies, as well as Genpharm L.P., MGG's new U.S. generics
business. DEY is a specialty pharmaceutical company focused on the
development, manufacturing and marketing of prescription drug
products for the treatment of respiratory diseases and
respiratory-related allergies.
"Mel's hard-working, team-oriented and objectives-based approach
to managing DEY will be of great benefit to our overall North
American business," said Hank Klakurka, President and Chief Executive
Officer, MGG. "His leadership will help enhance internal cooperation
and communication among the three North American companies,
strengthening our position in these important pharma markets."
Mr. Engle joined DEY in January 2002 and was elevated to President
and CEO in October 2002. Prior to DEY, he served as Chairman,
President and CEO of Anika Therapeutics, and President and CEO of US
Medical Products.
Mr. Engle is currently the Vice Chair of the "Thunderbird Global
Council" of the American Graduate School of International Management.
He received a BS from the University of Colorado and an MBA from the
University of Southern California. He currently serves on the boards
of the Queen of the Valley Hospital Foundation, the Community
Foundation of the Napa Valley and the Napa Valley College Foundation.
He is an honorary board member of the Napa Volunteer Center. Mr.
Engle, his wife and son reside in Napa.
About Merck KGaA
Merck is a global pharmaceutical and chemical company with sales
of EUR 5.9 billion in 2004, a history that began in 1668, and a
future shaped by 28,900 employees in 54 countries. Its success is
characterized by innovations from entrepreneurial employees. Merck's
operating activities come under the umbrella of Merck KGaA, in which
the Merck family holds a 73% interest and free shareholders own the
remaining 27%. The former U.S. subsidiary, Merck & Co., has been
completely independent of the Merck Group since 1917.
About DEY, L.P.
DEY, L.P. is a specialty pharmaceutical company focused on the
development, manufacturing and marketing of prescription drug
products for the treatment of respiratory diseases and
respiratory-related allergies. Since 1978, patients have benefited
from DEY's commitment to innovative and affordable health care
solutions. The Web sites for DEY include http://www.dey.com,
http://www.accuneb.com, http://www.curosurf.com,
http://www.duoneb.com, http://www.epipen.com.
Contact: Jonathan Mairs
             Ogilvy Public Relations
             +1-212-880-5200
Web site: http://www.dey.com

Contact:

Jonathan Mairs of Ogilvy Public Relations for Merck KGaA,
+1-212-880-5200

Plus de actualités: Merck Healthcare Germany GmbH
Plus de actualités: Merck Healthcare Germany GmbH
  • 24.04.2001 – 13:47

    Merck at In-Cosmetics 2001 in Dusseldorf/Germany

    Innovation in Cosmetics: Merck launches Emblica, a new plant-derived, free-radical-fighting ingredient for skin-care products Dusseldorf and Darmstadt/Germany (ots) - At the occasion of the international trade show In-Cosmetics 2001, being held in Dusseldorf/Germany from April 24-26, Merck KGaA today announced that it will launch Emblica, a patented combination of active ingredients extracted from the fruit of ...